The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The approval was supported by results from the global randomized phase 3 VERIFY trial involving 293 patients, which showed that patients receiving rusfertide demonstrated a higher clinical response rate, including maintained hematocrit control and reduced phlebotomy requirements, compared to placebo alongside standard care.
In this SOHO Insider video interview, Elias Jabbour, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer
The investigators, led by Ryan C Lynch, MD, of Fred Hutchinson Cancer Center in Seattle, Washington, published their findings in the Journal of Clinical Oncology.
The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal of Hematology & Oncology.
Clinical investigators are actively evaluating these novel agents across several strategic combinations and settings, Prof. Weisel explained.
“We have very interesting maintenance trials,” she noted, “where iberdomide is tested as a monotherapy or even in combination with monoclonal anti-CD38 antibodies.”
The approval is based on the Phase 2/3 ENERGY study, the full results of which were presented at the European Hematology Association 2026 meeting in June.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
